Hepatitis C: the path towards effective universal therapy

The Lancet

Volumn 388, Issue 10049, 2016, Pages 1051-1052

  Piroth, Lionel ^a   Rabaud, Christian ^b   Rey, David ^c   Schmit, Jean Luc ^d   Chirouze, Catherine ^e   Beck Wirth, Geneviève ^f   Robineau, Olivier ^g   Bani Sadr, Firouze ^h  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f Internal Medicine Department   (France)

^g CENTRE HOSPITALIER DE TOURCOING   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

DRUG COST; DRUG DEPENDENCE; DRUG EFFICACY; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRESCRIPTION; PRIORITY JOURNAL; SOCIAL SUPPORT; VIRAL CLEARANCE; VIRUS LOAD; HEPACIVIRUS; HEPATITIS B;

HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HUMANS;

EID: 84986277780     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31540-9     Document Type: Letter

References (0)